Analyst Price Targets — SRZN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 11:13 am | — | Cantor Fitzgerald | $40.00 | $25.09 | TheFly | Surrozen initiated with an Overweight at Cantor Fitzgerald |
| January 30, 2025 11:04 am | Matthew Caufield | H.C. Wainwright | $32.00 | $11.25 | TheFly | Surrozen initiated with a Buy at H.C. Wainwright |
| January 3, 2025 11:15 am | Yatin Suneja | Guggenheim | $45.00 | $17.45 | TheFly | Surrozen upgraded to Buy from Neutral at Guggenheim |
Latest News for SRZN
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that on April 24, 2026, Surrozen granted a non-statutory stock option for an aggregate of…
Surrozen (NASDAQ: SRZN - Get Free Report) and MediWound (NASDAQ: MDWD - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and profitability. Institutional and Insider Ownership 66.6% of Surrozen shares are
Surrozen (SRZN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Surrozen, Inc. (NASDAQ: SRZN - Get Free Report) major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the firm's stock in a transaction that occurred on Tuesday, March 24th. The shares were bought at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice of achievement of research milestone by Boehringer Ingelheim for SZN-413, triggering $5 million milestone payment Strengthened key leadership roles in 2025 to support long-term ophthalmology strategy…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SRZN.
U.S. House Trading
No House trades found for SRZN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.